Rivastigmine metabolite
Rivastigmine metabolite (NAP 226-90) is an acetylcholinesterase (AChE) inhibitor which is produced in kidney. Rivastigmine metabolite is promising for research of Alzheimer’s Disease[1].
Product Specifications
CAS Number
[139306-10-8]
Product Name Alternative
NAP 226-90
UNSPSC
12352005
Hazard Statement
H302, H315, H319, H335
Target
Cholinesterase (ChE)
Type
Reference compound
Related Pathways
Neuronal Signaling
Applications
Neuroscience-Neurodegeneration
Field of Research
Neurological Disease
Assay Protocol
https://www.medchemexpress.com/rivastigmine-metabolite.html
Purity
99.97
Solubility
DMSO : ≥ 200 mg/mL
Smiles
OC1=CC=CC([C@@H](N(C)C)C)=C1
Molecular Formula
C10H15NO
Molecular Weight
165.23
Precautions
H302, H315, H319, H335
References & Citations
[1]Polinsky RJ. Clinical pharmacology of rivastigmine: a new-generation acetylcholinesterase inhibitor for the treatment of Alzheimer's disease. Clin Ther. 1998 Jul-Aug;20 (4) :634-47.
Shipping Conditions
Blue Ice
Storage Conditions
-20°C (Powder, sealed storage, away from moisture)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Available Sizes
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
